Clinical trials


The Ndevana CRS was established in 2021 in the rural Ndevana community; approximately 45 kilometers from East London and 20 kilometers from King Williams Town and Bisho. This location was chosen based on the geographical aspects (rural community with clear land-scape demarcations) population composition, socio-economic indicators as proxy for popula-tion vulnerability, the epidemic profile (high HIV and STI prevalence), existing community rela-tionships, and previous experience working with this community.

The CRS comprises of a laboratory, pharmacy, clinical consulting rooms, and counselling rooms. a reception and participant waiting area, data storage facilities, a boardroom and offic-es. The CRS has two back-up generators (20 KVA and 10 KVA), which supply power to the entire facility in the event of power outages, and is equipped with water tanks to ensure conti-nuity in the event of water disruptions. There is also an alarm system and 24-hour on-site se-curity staff.



Current trials



Study Sponsor
A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy and Safety of MK-8527 Oral Once-Monthly as HIV-1 Preexposure Prophylaxis (MK-8527-011) MSD
A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy and Safety of MK-8527 Oral Once-Monthly as HIV-1 Preexposure Prophylaxis in Women (MK-8527-010) MSD/UW/Gates Foundation
Lenacapavir injection for HIV prevention in cisgender adolescent girls and young women (PURPOSE 1) Gilead
Lenacapavir injection for HIV prevention in men who have sex with men and transgender women (PURPOSE 2) Gilead


Completed trials



Study Sponsor
Study of oral weekly GS-1720 and GS-4182 compared with Biktarvy in people with HIV-1 who have not been treated
(2025-2026) 		Gilead
Implementation of oral pre-exposure prophylaxis for HIV prevention in cisgender adolescent girls and young women (INSIGHT)
(2021-2023) 		BMGF
The Community PrEP Study: a randomized control trial leveraging community-based platforms to improve access and adherence to pre-exposure prophylaxis to prevent HIV among adolescent girls and young women in South Africa
(2017-2023) 		NIH